CD83 is a cell surface molecule belonging to the immunoglobulin superfamily, primarily expressed on mature dendritic cells but also found on activated B cells and subsets of T cells. The CD83 antibody is used to target these cells, particularly in the context of immune modulation and therapeutic applications.
CD83 antibodies can modulate immune responses by targeting mature dendritic cells, which are crucial for antigen presentation and T cell activation. By depleting these cells, CD83 antibodies can suppress T cell responses, making them potential therapeutic agents for autoimmune diseases and transplant rejection.
Depletion of Mature Dendritic Cells: CD83 antibodies can induce antibody-dependent cellular cytotoxicity (ADCC), leading to the depletion of mature dendritic cells.
Immune Suppression: This depletion results in reduced T cell activation and proliferation, which can be beneficial in autoimmune conditions.
Selective Action: CD83 antibodies tend to spare resting B cells and immature dendritic cells, preserving some immune functions.
Recent studies have demonstrated the efficacy of CD83 antibodies in various models:
Autoimmune Diseases: In models of rheumatoid arthritis, CD83 antibodies have shown promise by reducing disease severity through immune suppression .
Transplantation: These antibodies may help prevent graft-versus-host disease by inhibiting alloreactive T cell responses .
CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses. Journal of Immunology, 2018;200(10):3460–3469. doi: 10.4049/jimmunol.1701595 .
Anti-Mouse CD83 Monoclonal Antibody Targeting Mature Dendritic Cells Provides Protection Against Collagen Induced Arthritis. Frontiers in Immunology, 2022;13:784528. doi: 10.3389/fimmu.2022.784528 .
KEGG: ath:AT5G54225
STRING: 3702.AT5G54225.1